Is the GLP-1 system a viable therapeutic target for weight reduction?

Reviews in Endocrine and Metabolic Disorders

Volumn 12, Issue 3, 2011, Pages 187-195

  Tong, Jenny ^a   Sandoval, Darleen A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Body weight regulation; Energy balance; Human; Incretin; Rodent

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; BODY MASS; CALORIC INTAKE; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; WEIGHT LOSS;

EID: 80054855642     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-011-9170-8     Document Type: Article

References (88)

1. Mc Intyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet. 1964;2:20-1.
2. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738-42. (Pubitemid 34778728)
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65.
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-72. (Pubitemid 34256388)
5. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206. (Pubitemid 47057766)
6. Drucker DJ. Glucagon and the glucagon-like peptides. Pancreas. 1990;5:484-8. (Pubitemid 20214988)
7. Goke R, Fehmann H, Goke B. Glucagon-like peptide-1 (7-36) amide is a new incretin/enterogastrone candidate. J Clin Investig. 1991;135:135-44.
8. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr. 2006;84:556-60. (Pubitemid 44713405)
9. Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Investig. 1997;27:10-6. (Pubitemid 27065167)
10. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000; 24:288-98. (Pubitemid 30137718)
11. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diab Care. 2004;27:1915-21. (Pubitemid 38989232)
12. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010; 123:468 e469-417.
13. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515-20. (Pubitemid 28084232)
14. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998;68:525-30. (Pubitemid 28402372)
15. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541-4. (Pubitemid 29249681)
16. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44:81-6. (Pubitemid 29143284)
17. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, et al. A meta-analysis of the effect ofglucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86:4382-9. (Pubitemid 32848563)
18. Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, et al. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr. 1999;81:273-9. (Pubitemid 29248498)
19. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels ofglucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001;25:781-92. (Pubitemid 32601369)
20. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-30. (Pubitemid 34233752)
21. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402-5.
22. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diab Care. 2005;28:1092-100. (Pubitemid 40616618)
23. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diab Care. 2004;27:2628-35. (Pubitemid 39441462)
24. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diab Care. 2005;28:1083-91. (Pubitemid 40616617)
25. Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or withoutmetformin. Diabetes Metab Res Rev. 2006;22:483-91. (Pubitemid 44774053)
26. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-86. (Pubitemid 351160260)
27. Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zuckerrats. Diabetologia. 2005;48:1380-5. (Pubitemid 41186105)
28. Bunck MC, Diamant M, Eliasson B, Corner A, Shaginian RM, Heine RJ. Exenatide affected circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010.
29. Kim D, Mac Conell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diab Care. 2007;30: 1487-93. (Pubitemid 46871159)
30. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424-9. (Pubitemid 34764798)
31. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diab Care. 2004;27:1335-42. (Pubitemid 38679980)
32. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202. (Pubitemid 34208381)
33. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm. 2005;62:173-81. (Pubitemid 40674548)
34. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-81.
35. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-78.
36. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diab Care. 2009;32:84-90.
37. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidi-nedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diab Care. 2009;32:1224-30.
38. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
39. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multina-tional, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
40. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects ofliraglutide in the treatment ofobesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-16.
41. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163-72.
42. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2003;12:87-100. (Pubitemid 36104645)
43. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diab Care. 2002;25:869-75. (Pubitemid 41094285)
44. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194-205. (Pubitemid 46206563)
45. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, random-izedtrial. Diab Care. 2007;30:217-23. (Pubitemid 46198322)
46. Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with compo-nent monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-85. (Pubitemid 46206561)
47. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in Hb A (1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24:955-61. (Pubitemid 47301637)
48. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther. 2009;26:488-99.
49. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007;56:8-15.
50. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes. 2007;56:3006-13. (Pubitemid 350223636)
51. Jin SL, Han VKM, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagonlike peptide 1, glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol. 1988;271.
52. Han VK, Hynes MA, Jin C, Towle AC, Lauder JM, Lund PK. Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain. J Neurosci Res. 1986;16:97-107. (Pubitemid 16050410)
53. Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res. 2010.
54. Van Dijk G, Thiele TE, Donahey JC, Campfield LA, Smith FJ, Burn P, et al. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol. 1996;271:R1096-100.
55. Hayes MR, Bradley L, Grill HJ. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control offood intake by mediating gastric satiation signaling. Endocrinology. 2009;150:2654-9.
56. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43-52. (Pubitemid 34743464)
57. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009;29:5916-25.
58. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008;149:4768-77.
59. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation offeeding [see comments]. Nature. 1996;379:69-72. (Pubitemid 26008136)
60. Donahey JC, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 1998;779:75-83. (Pubitemid 28039941)
61. Thiele TE, Seeley RJ, D'Alessio D, Eng J, Bernstein IL, Woods SC, et al. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res. 1998;801: 164-70. (Pubitemid 28401660)
62. Van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL. Glucagon-like peptide-1 and satiety [letter; comment]. Nature. 1997;385:214. (Pubitemid 27043713)
63. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848-56.
64. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of CNS GLP-1 in the control of food intake and the mediation of visceral illness. J Neurosci. 2002;22:10470-6. (Pubitemid 35416883)
65. Mc Mahon LR, Wellman PJ. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol Biochem Behav. 1997;58:673-7. (Pubitemid 27438122)
66. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes. 2008;57:2046-54.
67. Schusdziarra V, Zimmermann JP, Schick RR. Importance of orexigenic counter-regulation for multiple targeted feeding inhi-bition. Obes Res. 2004;12:627-32. (Pubitemid 41132505)
68. Furuse M, Matsumoto M, Mori R, Sugahara K, Kano K, Hasegawa S. Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injec-tion ofglucagon-like peptide-1 in the neonatal chick. Brain Res. 1997;764:289-92. (Pubitemid 27380673)
69. Tritos NA, Vicent D, Gillette J, Ludwig DS, Flier ES, Maratos-Flier E. Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Diabetes. 1998;47:1687-92. (Pubitemid 28476241)
70. Edwards CM, Abbott CR, Sunter D, Kim M, Dakin CL, Murphy KG, et al. Cocaine- and amphetamine-regulated transcript, glucagon-like peptide-1 and corticotrophin releasing factor inhibit feeding via agouti-related protein independent pathways in the rat. Brain Res. 2000;866:128-34. (Pubitemid 30313015)
71. Seeley R, Yagaloff K, Fisher S, Burn P, Thiele T, van Dijk G, et al. Melanocortin receptors in leptin effects. Nature. 1997; 390:349.
72. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006;55:3387-93. (Pubitemid 44923597)
73. Huo L, Gamber KM, Grill HJ, Bjorbaek C. Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats. Endocrinology. 2008;149:492-7. (Pubitemid 351159324)
74. Orskov C, Puolsen S, Moller M, Holst JJ. Glucagon-like peptide 1 receptors in the subformical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes. 1996;45:832-5. (Pubitemid 26168585)
75. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypep-tide, in rat nodose ganglion cells. Auton Neurosci. 2004;110: 36-43. (Pubitemid 38180536)
76. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of GLP-1. Am J Physiol. 1996;271:E808-13.
77. Kakei M, Yada T, Nakagawa A, Nakabayashi H. Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons. Auton Neurosci. 2002; 102:39-44. (Pubitemid 35305005)
78. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology. 2007;148:4965-73. (Pubitemid 47481523)
79. Kim DH, D'Alessio DA, Woods SC, Seeley RJ. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept. 2009;155:110M4.
80. Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50:341-8. (Pubitemid 34161049)
81. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282: G424-31. (Pubitemid 34651657)
82. Delgado-Aros S, Vella A, Camilleri M, Low PA, Burton DD, Thomforde GM, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil. 2003;15: 435-43. (Pubitemid 36876259)
83. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69:737-44.
84. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointes-tinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56:1475-80. (Pubitemid 46715627)
85. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719-25. (Pubitemid 36733545)
86. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ. Differences in the central anorectic effects of GLP-1 and exendin-4 in rats. Diabetes. 2009.
87. Lachey JL, D'Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats andmice. Endocrinology 2005;146:458-62. (Pubitemid 40051771)
88. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749-57.